Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs

Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs

• GLP-1 receptor agonists showed CV benefit compared to placebo. • SGLT-2 inhibitors resulted in a significant reduction in heart failure hospitalizations. • DPP-4 inhibitors are comparable to placebo in terms of CV safety. • The NMA showed no significant differences among the medications of each cl...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients. - 2016. - Amsterdam [u.a.]
1. Verfasser: Alfayez, Osamah M. (VerfasserIn)
Weitere Verfasser: Al Yami, Majed S. (BerichterstatterIn), Alshibani, Mohannad (BerichterstatterIn), Fallatah, Saad B. (BerichterstatterIn), Al Khushaym, Nasser M. (BerichterstatterIn), Alsheikh, Razan (BerichterstatterIn), Alkhatib, Nimer (BerichterstatterIn)
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2019
Zugriff auf das übergeordnete Werk:A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients
Schlagworte:T2DM CV NMA MACE GLP-1 agonist DPP-4 inhibitor SGLT-2 inhibitor CVOT MI HF
Umfang:8
LEADER 01000caa a22002652 4500
001 ELV046547231
003 DE-627
005 20230624123650.0
007 cr uuu---uuuuu
008 191021s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.pcd.2019.01.003  |2 doi 
028 5 2 |a GBV00000000000598.pica 
035 |a (DE-627)ELV046547231 
035 |a (ELSEVIER)S1751-9918(18)30309-7 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
082 0 4 |a 630  |q VZ 
082 0 4 |a 640  |q VZ 
082 0 4 |a 590  |q VZ 
082 0 4 |a 610  |q VZ 
082 0 4 |a 600  |q VZ 
084 |a 50.70  |2 bkl 
100 1 |a Alfayez, Osamah M.  |e verfasserin  |4 aut 
245 1 0 |a Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs 
264 1 |c 2019 
300 |a 8 
336 |a nicht spezifiziert  |b zzz  |2 rdacontent 
337 |a nicht spezifiziert  |b z  |2 rdamedia 
338 |a nicht spezifiziert  |b zu  |2 rdacarrier 
520 |a • GLP-1 receptor agonists showed CV benefit compared to placebo. • SGLT-2 inhibitors resulted in a significant reduction in heart failure hospitalizations. • DPP-4 inhibitors are comparable to placebo in terms of CV safety. • The NMA showed no significant differences among the medications of each class. 
650 7 |a T2DM  |2 Elsevier 
650 7 |a CV  |2 Elsevier 
650 7 |a NMA  |2 Elsevier 
650 7 |a MACE  |2 Elsevier 
650 7 |a GLP-1 agonist  |2 Elsevier 
650 7 |a DPP-4 inhibitor  |2 Elsevier 
650 7 |a SGLT-2 inhibitor  |2 Elsevier 
650 7 |a CVOT  |2 Elsevier 
650 7 |a MI  |2 Elsevier 
650 7 |a HF  |2 Elsevier 
700 1 |a Al Yami, Majed S.  |4 oth 
700 1 |a Alshibani, Mohannad  |4 oth 
700 1 |a Fallatah, Saad B.  |4 oth 
700 1 |a Al Khushaym, Nasser M.  |4 oth 
700 1 |a Alsheikh, Razan  |4 oth 
700 1 |a Alkhatib, Nimer  |4 oth 
773 0 8 |i Enthalten in  |n Elsevier  |a David, Lauren A. ELSEVIER  |t A pilot randomized controlled trial examining the feasibility, acceptability, and efficacy of Adapted Motivational Interviewing for post-operative bariatric surgery patients  |d 2016  |g Amsterdam [u.a.]  |w (DE-627)ELV024210129 
773 1 8 |g volume:13  |g year:2019  |g number:3  |g pages:204-211  |g extent:8 
856 4 0 |u https://doi.org/10.1016/j.pcd.2019.01.003  |3 Volltext 
912 |a GBV_USEFLAG_U 
912 |a GBV_ELV 
912 |a SYSFLAG_U 
912 |a GBV_ILN_24 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_227 
912 |a GBV_ILN_350 
936 b k |a 50.70  |j Energie: Allgemeines  |q VZ 
951 |a AR 
952 |d 13  |j 2019  |e 3  |h 204-211  |g 8